Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation..
The emergence of advanced therapies [eg, biologics, Janus kinase inhibitors] over the past few decades has revolutionised the treatment of ulcerative colitis. However, the limitations of these therapies leave an unmet need for safer and more effective or convenient treatment options. There is growing interest in the development of novel oral small molecule therapies for the treatment of ulcerative colitis. Ozanimod is an oral small molecule therapy that is approved in the USA, the European Union, and other countries as the first sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active ulcerative colitis in adults. This review provides guidance for ozanimod use for the treatment of ulcerative colitis, based on the prescribing information, clinical trial and real-world data, and the authors' clinical experiences. This guidance outlines patient characteristics to consider when deciding if ozanimod treatment is suitable and describes how to educate patients on risks and best practices. It also details the nature and frequency of monitoring during treatment, which should be adapted to the individual patient based on pre-existing risk factors and events that possibly occur during treatment. This review also provides insights into the patient characteristics and clinical scenarios best suited for ozanimod treatment, based on its efficacy, safety profile, and risks compared with other therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 17(2023), 12 vom: 30. Dez., Seite 2012-2025 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sands, Bruce E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunologic Factors |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjad112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359372082 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359372082 | ||
| 003 | DE-627 | ||
| 005 | 20240122231842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjad112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM359372082 | ||
| 035 | |a (NLM)37436357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sands, Bruce E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. | ||
| 520 | |a The emergence of advanced therapies [eg, biologics, Janus kinase inhibitors] over the past few decades has revolutionised the treatment of ulcerative colitis. However, the limitations of these therapies leave an unmet need for safer and more effective or convenient treatment options. There is growing interest in the development of novel oral small molecule therapies for the treatment of ulcerative colitis. Ozanimod is an oral small molecule therapy that is approved in the USA, the European Union, and other countries as the first sphingosine 1-phosphate receptor modulator for the treatment of moderately to severely active ulcerative colitis in adults. This review provides guidance for ozanimod use for the treatment of ulcerative colitis, based on the prescribing information, clinical trial and real-world data, and the authors' clinical experiences. This guidance outlines patient characteristics to consider when deciding if ozanimod treatment is suitable and describes how to educate patients on risks and best practices. It also details the nature and frequency of monitoring during treatment, which should be adapted to the individual patient based on pre-existing risk factors and events that possibly occur during treatment. This review also provides insights into the patient characteristics and clinical scenarios best suited for ozanimod treatment, based on its efficacy, safety profile, and risks compared with other therapies | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a S1P receptor modulator | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 4 | |a ozanimod | |
| 650 | 7 | |a ozanimod |2 NLM | |
| 650 | 7 | |a Z80293URPV |2 NLM | |
| 650 | 7 | |a Indans |2 NLM | |
| 650 | 7 | |a Oxadiazoles |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Schreiber, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Blumenstein, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Chiorean, Michael V |e verfasserin |4 aut | |
| 700 | 1 | |a Ungaro, Ryan C |e verfasserin |4 aut | |
| 700 | 1 | |a Rubin, David T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 17(2023), 12 vom: 30. Dez., Seite 2012-2025 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:12 |g day:30 |g month:12 |g pages:2012-2025 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjad112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 12 |b 30 |c 12 |h 2012-2025 | ||